@article {Tannerbjophthalmol-2021-320631, author = {Alexander Tanner and Fadi Haddad and Julia Fajardo-Sanchez and Ethan Nguyen and Kai Xin Thong and Sarah Ah-Moye and Nicole Perl and Mohammed Abu-Bakra and Avinash Kulkarni and Sameer Trikha and Gerassimos Lascaratos and Miles Parnell and Obeda Kailani and Anthony J King and Pavi Agrawal and Richard Stead and Konstantinos Giannouladis and Ian Rodrigues and Saurabh Goyal and Pirro G Hysi and Sheng Lim and Cynthia Yu-Wai-Man}, title = {One-year surgical outcomes of the PreserFlo MicroShunt in glaucoma: a multicentre analysis}, elocation-id = {bjophthalmol-2021-320631}, year = {2022}, doi = {10.1136/bjophthalmol-2021-320631}, publisher = {BMJ Publishing Group Ltd}, abstract = {Background/aims To evaluate the efficacy and safety of the PreserFlo MicroShunt glaucoma device in a multicentre cohort study.Methods All consecutive patients who received the microshunt with mitomycin-C (MMC) 0.4 mg/mL from May 2019 to September 2020 in three UK tertiary centres. Primary outcome at 1 year was a complete success, with failure defined as intraocular pressure (IOP) \>21 mmHg or \<20\% reduction, IOP<=5 mmHg with any decreased vision on two consecutive visits, reoperation or loss of light perception vision. Secondary outcomes were IOP, best-corrected visual acuity, medications, complications, interventions and reoperations. We also performed subgroup analyses for severe glaucoma and assessed risk factors for failure.Results 104 eyes had 1-year follow-up. Complete and qualified success at 1 year were achieved in 51.9\% (N=54) and 16.4\% (N=17), respectively, and failure occurred in 31.7\% (N=33). There was a significant reduction in IOP (mmHg) from preoperatively (23.4{\textpm}0.8, N=104) to 12 months (14.7{\textpm}0.6, N=104) (p\<0.0001). Antiglaucoma medications also decreased from preoperatively (3.4{\textpm}0.1, N=104) to 12 months (0.7{\textpm}0.1, N=104) (p\<0.0001). Multivariate analyses showed an association between higher mean deviation and failure (HR 1.055, 95\% CI 1.0075 to 1.11, p=0.0227). Complications were hypotony (19.2\%; N=20), choroidal detachments (10.6\%; N=11), hyphaema (5.8\%; N=6) and bleb leak (5.8\%; N=6). Needling and 5-fluorouracil injections were performed in 12.5\% (N=13) and 33.7\% (N=35), respectively, and 11.5\% (N=12) required revision surgery.Conclusion The PreserFlo MicroShunt with MMC 0.4 mg/mL showed an overall success rate of 68.3\% at 1 year, and led to significant IOP and medication reduction with a low rate of adverse effects.All data relevant to the study are included in the article or uploaded as online supplemental information. Not applicable.}, issn = {0007-1161}, URL = {https://bjo.bmj.com/content/early/2022/03/31/bjophthalmol-2021-320631}, eprint = {https://bjo.bmj.com/content/early/2022/03/31/bjophthalmol-2021-320631.full.pdf}, journal = {British Journal of Ophthalmology} }